0000899243-19-006334.txt : 20190305 0000899243-19-006334.hdr.sgml : 20190305 20190305210638 ACCESSION NUMBER: 0000899243-19-006334 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190301 FILED AS OF DATE: 20190305 DATE AS OF CHANGE: 20190305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knappertz Volker CENTRAL INDEX KEY: 0001754122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35892 FILM NUMBER: 19661031 MAIL ADDRESS: STREET 1: SOVEREIGN HOUSE, VISION PARK, HISTON CITY: CAMBRIDGE STATE: X0 ZIP: CB249BZ ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GW PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001351288 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 BUSINESS PHONE: 44 1223 266800 MAIL ADDRESS: STREET 1: SOVEREIGN HOUSE STREET 2: VISION PARK CITY: HISTON, CAMBRIDGE CB24 9BZ STATE: X0 ZIP: 00000 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-03-01 0 0001351288 GW PHARMACEUTICALS PLC GWPH 0001754122 Knappertz Volker SOVEREIGN HOUSE, VISION PARK, HISTON CAMBRIDGE X0 CB24 9BZ UNITED KINGDOM 0 1 0 0 Chief Medical Officer Ordinary Shares 2019-03-01 4 S 0 3732 14.46 D 8736 D Stock Options 14.33 2019-03-01 4 A 0 48252 0.00 A 2022-03-01 2029-03-01 Ordinary Shares 48252 48252 D Stock Options 0.0013 2019-03-01 4 A 0 91584 0.00 A 2022-03-01 2023-03-15 Ordinary Shares 91584 91584 D Stock Options 0.0013 2019-03-01 4 A 0 6864 0.00 A 2020-03-01 Ordinary Shares 6864 6864 D Stock Options 0.0013 2019-03-01 4 A 0 6864 0.00 A 2021-03-01 Ordinary Shares 6864 6864 D Stock Options 0.0013 2019-03-01 4 A 0 6864 0.00 A 2022-03-01 Ordinary Shares 6864 6864 D Stock Options 0.0013 2019-03-01 4 A 0 6864 0.00 A 2023-03-01 Ordinary Shares 6864 6864 D Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. The price reported in Column 4 is price per ordinary share converted from price per ADS. Granted pursuant to the Issuer's Long-Term Incentive Plan. The reported options are options to purchase ADSs. The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. These stock options will vest automatically on exercisable date. /s/ Volker Knappertz 2019-03-05